Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy (Q22252578)

7 February 2023

Jin Nakahara

1

Jin

Nakahara

1 reference

1033460038

7 February 2023

Michiko Maeda

series ordinal

2

author given names

Michiko

author last names

Maeda

1 reference

1033460038

7 February 2023

Sadakazu Aiso

series ordinal

3

author given names

Sadakazu

author last names

Aiso

1 reference

1033460038

Clinical Reviews in Allergy & Immunology

7 February 2023

language of work or name

English

0 references

publication date

22 December 2011

0 references

published in

0 references

volume

42

0 references

issue

1

0 references

page(s)

26-34

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s12016-011-8287-6

0 references

cites work

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Natural history of multiple sclerosis: a unifying concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Multiple sclerosis: distribution of inflammatory cells in newly forming lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Control of TH17 cells occurs in the small intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Lipopolysaccharide-activated microglia induce death of oligodendrocyte progenitor cells and impede their development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Onset of multiple sclerosis associated with anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Invited article: human natural autoantibodies in the treatment of neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Oligodendrocytes: biology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Age at disability milestones in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Analysis of current multiple sclerosis registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Trends in survival and cause of death in Danish patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Gray matter atrophy in multiple sclerosis: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Cervical cord and brain grey matter atrophy independently associate with long-term MS disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Cortical lesions in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

The blood-brain barrier in cortical multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-011-8287-6

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

21 January 2018

1 reference

12 December 2020

A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.

1 reference

12 December 2020

Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis

1 reference

12 December 2020

Stimulation of adult oligodendrogenesis by myelin-specific T cells

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Multiple sclerosis and Alzheimer's disease

1 reference

12 December 2020

Spinal cord atrophy and disability in multiple sclerosis

1 reference

12 December 2020

Gray matter atrophy is related to long-term disability in multiple sclerosis

1 reference

12 December 2020

Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study

1 reference

12 December 2020

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.

1 reference

12 December 2020

Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1

1 reference

12 December 2020